Akdemir Eyub Y, Gurdikyan Selin, Rubens Muni, Abrams Kevin J, Sidani Charif, Chaneles Margaret C, Hall Matthew D, Press Robert H, Wieczorek D Jay, Tolakanahalli Ranjini, Gutierrez Alonso N, Gal Omer, La Rosa Alonso, Kutuk Tugce, McDermott Michael W, Odia Yazmin, Mehta Minesh P, Kotecha Rupesh
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.
Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Neuro Oncol. 2025 Mar 7;27(3):854-864. doi: 10.1093/neuonc/noae232.
Stereotactic radiosurgery (SRS) for patients with brain metastases (BM) is associated with a risk of distant intracranial failure (DIF). This study evaluates the impact of integrating dedicated 3D fast/turbo spin echo (3D-TSE) sequences to MPRAGE in BM detection and DIF prolongation in a histology-agnostic patient cohort.
The study population included adults treated with SRS from February 2019 to January 2024 who underwent MPRAGE alone or dual sequence with the addition of 3D-TSE starting from February 2020. Median times to DIF were estimated using the Kaplan-Meier method.
The 216 study patients who underwent 332 SRS courses for 1456 BM imaged with MPRAGE and 3D-TSE (primary cohort) were compared to a control cohort (92 patients, 135 SRS courses, 462 BM). In the session-wise analysis, the median time to DIF between the cohorts was significantly prolonged in the primary vs. control cohorts (11.4 vs. 6.8 months, P = .029), more pronounced in the subgroups with 1-4 metastases (14.7 vs. 8.1 months, P = .008) and with solitary BM (36.4 vs. 10.9 months, P = .001). While patients relapsing on immunotherapy or targeted therapy did not significantly benefit from 3D-TSE (7.2 vs. 5.7 months, P = .280), those who relapsed on chemotherapy or who were off systemic therapy (including synchronous metastases) exhibited a trend toward longer time to DIF with 3D-TSE integration (14.7 vs. 7.9 months, P = .057).
Implementing 3D-TSE sequences into SRS practice increases BM detection across all patients and translates into clinical relevance by prolonging time to DIF, particularly in those with limited intracranial disease and those not receiving central nervous system-active agents.
立体定向放射外科(SRS)治疗脑转移瘤(BM)患者存在远处颅内失败(DIF)风险。本研究评估了在组织学未知的患者队列中,将专用3D快速/涡轮自旋回波(3D-TSE)序列与MPRAGE序列相结合对BM检测及延长DIF时间的影响。
研究人群包括2019年2月至2024年1月接受SRS治疗的成年人,其中部分患者仅接受MPRAGE序列检查,部分患者自2020年2月起接受MPRAGE序列联合3D-TSE序列检查。采用Kaplan-Meier法估计DIF的中位时间。
对216例接受332次SRS治疗、共1456个BM且进行了MPRAGE和3D-TSE成像的研究患者(主要队列)与一个对照队列(92例患者,135次SRS治疗,462个BM)进行比较。在逐次分析中,主要队列与对照队列相比,DIF的中位时间显著延长(11.4个月对6.8个月,P = 0.029),在有1-4个转移灶的亚组(14.7个月对8.1个月,P = 0.008)和单发BM亚组(36.4个月对10.9个月,P = 0.001)中更为明显。虽然在免疫治疗或靶向治疗中复发的患者未从3D-TSE中显著获益(7.2个月对5.7个月,P = 0.280),但在化疗中复发或未接受全身治疗(包括同时性转移)的患者,3D-TSE联合使用有使DIF时间延长的趋势(14.7个月对7.9个月,P = 0.057)。
在SRS实践中实施三维TSE序列可提高所有患者的BM检测率,并通过延长DIF时间转化为临床相关性,特别是在颅内疾病有限的患者和未接受中枢神经系统活性药物治疗的患者中。